What is the share price of IPCA Laboratories Ltd (IPCALAB) today?
The share price of IPCALAB as on 17th September 2025 is ₹1310. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on IPCA Laboratories Ltd (IPCALAB) share?
The past returns of IPCA Laboratories Ltd (IPCALAB) share are- Past 1 week: -1.86%
- Past 1 month: -4.01%
- Past 3 months: -3.74%
- Past 6 months: -0.47%
- Past 1 year: -10.17%
- Past 3 years: 52.31%
- Past 5 years: 18.93%
What are the peers or stocks similar to IPCA Laboratories Ltd (IPCALAB)?
The peers or stocks similar to IPCA Laboratories Ltd (IPCALAB) include:What is the dividend yield % of IPCA Laboratories Ltd (IPCALAB) share?
The current dividend yield of IPCA Laboratories Ltd (IPCALAB) is 0.30.What is the market cap of IPCA Laboratories Ltd (IPCALAB) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of IPCA Laboratories Ltd (IPCALAB) is ₹33273.31 Cr as of 17th September 2025.What is the 52 week high and low of IPCA Laboratories Ltd (IPCALAB) share?
The 52-week high of IPCA Laboratories Ltd (IPCALAB) is ₹1755.90 and the 52-week low is ₹1168.20.What is the PE and PB ratio of IPCA Laboratories Ltd (IPCALAB) stock?
The P/E (price-to-earnings) ratio of IPCA Laboratories Ltd (IPCALAB) is 45.11. The P/B (price-to-book) ratio is 3.97.Which sector does IPCA Laboratories Ltd (IPCALAB) belong to?
IPCA Laboratories Ltd (IPCALAB) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy IPCA Laboratories Ltd (IPCALAB) shares?
You can directly buy IPCA Laboratories Ltd (IPCALAB) shares on Tickertape. Simply sign up, connect your demat account and place your order.
IPCA Laboratories Ltd
IPCALAB Share Price
1,310.000.11% (-1.50)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
IPCALAB Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
IPCALAB Performance & Key Metrics
IPCALAB Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 42.73 | 3.97 | 0.30% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 37.23 | 5.88 | 0.58% |
75%
Analysts have suggested that investors can buy this stock
from 16 analysts
Price Upside
Earnings Growth
Rev. Growth
IPCALAB Company Profile
Ipca Laboratories Limited is engaged in pharmaceuticals business. The Company is a manufacturer and supplier of over 10 active pharmaceutical ingredients (APIs).
SUNPHARMA
PE Ratio
35.36
35.36
1Y Return
13.55%
13.55%
Buy Reco %
86.11
86.11
CIPLA
PE Ratio
23.88
23.88
1Y Return
6.05%
6.05%
Buy Reco %
66.67
66.67
TORNTPHARM
PE Ratio
62.61
62.61
1Y Return
2.36%
2.36%
Buy Reco %
76.00
76.00
DRREDDY
PE Ratio
19.29
19.29
1Y Return
1.43%
1.43%
Buy Reco %
40.00
40.00
MANKIND
PE Ratio
53.28
53.28
1Y Return
4.62%
4.62%
Buy Reco %
81.25
81.25
IPCALAB Sentiment Analysis
IPCALAB Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
IPCALAB Stock Summary · August 2025
In Q1 FY26, the company demonstrated resilience with a 26% increase in standalone net profit, driven by strong performance in chronic therapies and a notable 37% growth in the European market, despite facing challenges in the cardiovascular segment and regulatory issues in Asia and Brazil. While the domestic business grew by 10% and market share slightly improved, operational hurdles such as excess inventory in the UK and initial losses from new subsidiaries, including one in Germany, pose short-term risks. However, the strategic focus on expanding product offerings and enhancing operational capacity suggests a commitment to long-term growth, particularly in the promising US generics market, where incremental revenue gains indicate potential for future success.
IPCALAB Stock Growth Drivers
IPCALAB Stock Growth Drivers
7Strong Domestic Business Growth
In the first quarter of FY '26, the company reported a domestic business growth of
Robust Export Performance
The export sector demonstrated significant growth, with the branded formulation business increasing by 10% to
IPCALAB Stock Challenges
IPCALAB Stock Challenges
6Decline in Market Performance
Unichem has experienced significant declines in its Asia and Brazil markets, with business in Asia
Increased Provisions and Expenses
The company has made an additional provision of Rs. 12 crores due to currency fluctuations
IPCALAB Forecast
IPCALAB Forecasts
Price
Revenue
Earnings
IPCALAB Share Price Forecast
IPCALAB Share Price Forecast
2025
Current
₹1,311.50
Baseline
Forecast for Sep 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹1,311.50
Baseline
Forecast for Sep 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
IPCALAB Company Revenue Forecast
IPCALAB Company Revenue Forecast
2025
Current
₹9.03
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2025
Current
₹9.03
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
IPCALAB Stock EPS (Earnings Per Share) Forecast
IPCALAB Stock EPS (Earnings Per Share) Forecast
2025
Current
₹29.08
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹29.08
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
IPCALAB
IPCALAB
Income
Balance Sheet
Cash Flow
Annual Normal View
IPCALAB Income Statement
IPCALAB Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 3,168.94 | 3,299.56 | 3,803.37 | 4,686.03 | 5,482.83 | 5,896.36 | 6,369.94 | 7,897.82 | 9,032.39 | 9,260.66 | ||||||||||
Raw Materials | 1,115.71 | 1,101.28 | 1,355.15 | 1,820.25 | 1,923.09 | 2,144.50 | 2,205.84 | 2,706.39 | 2,824.60 | 7,611.02 | ||||||||||
| Power & Fuel Cost | 151.00 | 161.92 | 176.50 | 201.22 | 207.10 | 242.12 | 283.74 | 333.97 | 351.23 | |||||||||||
| Employee Cost | 695.98 | 735.88 | 787.40 | 921.23 | 1,013.57 | 1,177.39 | 1,287.64 | 1,708.43 | 1,983.99 | |||||||||||
| Selling & Administrative Expenses | 596.75 | 598.72 | 524.85 | 545.44 | 575.16 | 641.87 | 704.69 | 853.53 | 977.48 | |||||||||||
| Operating & Other expenses | 147.58 | 205.93 | 208.35 | 228.73 | 153.49 | 311.14 | 832.99 | 954.84 | 1,278.29 | |||||||||||
EBITDA | 461.92 | 495.83 | 751.12 | 969.16 | 1,610.42 | 1,379.34 | 1,055.04 | 1,340.66 | 1,616.80 | 1,649.64 | ||||||||||
| Depreciation/Amortization | 172.95 | 177.73 | 182.42 | 210.50 | 209.17 | 232.42 | 261.56 | 357.24 | 397.82 | 398.99 | ||||||||||
| PBIT | 288.97 | 318.10 | 568.70 | 758.66 | 1,401.25 | 1,146.92 | 793.48 | 983.42 | 1,218.98 | 1,250.65 | ||||||||||
| Interest & Other Items | 26.91 | 27.57 | 22.24 | 19.77 | 12.27 | 11.20 | 48.19 | 140.75 | 87.84 | 79.39 | ||||||||||
| PBT | 262.06 | 290.53 | 546.46 | 738.89 | 1,388.98 | 1,135.72 | 745.29 | 842.67 | 1,131.14 | 1,171.26 | ||||||||||
| Taxes & Other Items | 67.52 | 51.11 | 101.63 | 132.57 | 248.97 | 251.64 | 273.97 | 295.32 | 393.46 | 392.61 | ||||||||||
| Net Income | 194.54 | 239.42 | 444.83 | 606.32 | 1,140.01 | 884.08 | 471.32 | 547.35 | 737.68 | 778.65 | ||||||||||
| EPS | 7.71 | 12.65 | 35.23 | 47.99 | 59.99 | 34.85 | 18.58 | 21.57 | 29.08 | 30.69 | ||||||||||
| DPS | 0.50 | 1.00 | 3.00 | 5.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | ||||||||||
| Payout ratio | 0.06 | 0.08 | 0.09 | 0.10 | 0.07 | 0.11 | 0.22 | 0.19 | 0.14 | 0.13 |
IPCALAB Company Updates
IPCALAB Stock Peers
IPCALAB Past Performance & Peer Comparison
IPCALAB Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| IPCA Laboratories Ltd | 45.11 | 3.97 | 0.30% |
| Sun Pharmaceutical Industries Ltd | 35.36 | 5.33 | 0.99% |
| Cipla Ltd | 23.88 | 4.02 | 1.03% |
| Torrent Pharmaceuticals Ltd | 62.61 | 15.76 | 0.91% |
IPCALAB Stock Price Comparison
Compare IPCALAB with any stock or ETFCompare IPCALAB with any stock or ETF
IPCALAB
IPCALAB Holdings
IPCALAB Shareholdings
IPCALAB Promoter Holdings Trend
IPCALAB Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
IPCALAB Institutional Holdings Trend
IPCALAB Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
IPCALAB Shareholding Pattern
IPCALAB Shareholding Pattern
IPCALAB Shareholding History
IPCALAB Shareholding History
Foreign Institutions
Mutual Funds Invested in IPCALAB
Mutual Funds Invested in IPCALAB
No mutual funds holding trends are available
Top 5 Mutual Funds holding IPCA Laboratories Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.2654% | Percentage of the fund’s portfolio invested in the stock 4.62% | Change in the portfolio weight of the stock over the last 3 months 0.15% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 6/32 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0872% | Percentage of the fund’s portfolio invested in the stock 1.15% | Change in the portfolio weight of the stock over the last 3 months 1.15% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 32/58 (-1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0540% | Percentage of the fund’s portfolio invested in the stock 2.81% | Change in the portfolio weight of the stock over the last 3 months 2.81% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 12/31 (+10) |
Compare 3-month MF holding change on Screener
smallcases containing IPCALAB stock
smallcases containing IPCALAB stock
Looks like this stock is not in any smallcase yet.
IPCALAB Events
IPCALAB Events
IPCALAB Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
IPCALAB has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.30%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹3.05 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
IPCALAB Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
IPCALAB has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.30%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹3.05 every year
IPCALAB Upcoming Dividends
IPCALAB Upcoming Dividends
No upcoming dividends are available
IPCALAB Past Dividends
IPCALAB Past Dividends
Cash Dividend
Ex DateEx DateAug 5, 2025
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Aug 5, 2025
Cash Dividend
Ex DateEx DateNov 27, 2024
Interim
Interim | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Nov 27, 2024
Cash Dividend
Ex DateEx DateAug 6, 2024
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Aug 6, 2024
Cash Dividend
Ex DateEx DateNov 22, 2023
Interim
Interim | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Nov 22, 2023
Cash Dividend
Ex DateEx DateNov 22, 2022
Interim
Interim | Div/Share: ₹4.00
Dividend/Share
₹4.00
Ex DateEx Date
Nov 22, 2022
IPCALAB Stock News & Opinions
IPCALAB Stock News & Opinions
Articles & Videos
Earnings
Ipca Laboratories consolidated net profit rises 21.31% in the June 2025 quarter
Net profit of Ipca Laboratories rose 21.31% to Rs 233.21 crore in the quarter ended June 2025 as against Rs 192.24 crore during the previous quarter ended June 2024. Sales rose 10.33% to Rs 2308.85 crore in the quarter ended June 2025 as against Rs 2092.63 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales2308.852092.63 10 OPM %18.0418.77 - PBDT430.57389.28 11 PBT330.51290.39 14 NP233.21192.24 21 Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Ipca Labs Q1 PAT climbs 21% YoY to Rs 233 cr
Revenue from operations jumped 10.33% year on year to Rs 2,308.85 crore in the quarter ended 30 June 2025. Profit before tax (PBT) increased 13.81% to Rs 330.51 crore in Q1 FY25, compared with Rs 290.39 crore in Q1 FY25. EBITDA stood at Rs 424.58 crore in Q1 FY26, registering the growth of 10%, compared with Rs 387.49 crore in Q1 FY25. Consolidated EBITDA margin (before forex (gain)/loss, other income and exceptional items) stood at 18.39% in Q1 FY26 as against at 18.52% in Q1 FY25. During the quarter, total formulations were at Rs 1,410.62 crore, up 11% YoY. Domestic business stood at Rs 961.01 crore (up 10% YoY). Ipca Laboratories is engaged in the manufacturing and marketing of pharmaceuticals. Shares of Ipca Laboratories fell 3.62% to Rs 1,334.40 on the BSE. Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Ipca Laboratories schedules board meeting
Ipca Laboratories will hold a meeting of the Board of Directors of the Company on 11 August 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Volumes soar at Ipca Laboratories Ltd counter
Coforge Ltd, Persistent Systems Ltd, ZF Commercial Vehicle Control System India Ltd, Tata Consumer Products Ltd are among the other stocks to see a surge in volumes on BSE today, 24 July 2025.Ipca Laboratories Ltd recorded volume of 28541 shares by 10:45 IST on BSE, a 9.69 times surge over two-week average daily volume of 2946 shares. The stock gained 3.70% to Rs.1,516.10. Volumes stood at 2842 shares in the last session.Coforge Ltd saw volume of 2.32 lakh shares by 10:45 IST on BSE, a 8.03 fold spurt over two-week average daily volume of 28887 shares. The stock dropped 7.73% to Rs.1,706.20. Volumes stood at 39060 shares in the last session.Persistent Systems Ltd witnessed volume of 63372 shares by 10:45 IST on BSE, a 5.48 times surge over two-week average daily volume of 11561 shares. The stock dropped 8.86% to Rs.5,108.45. Volumes stood at 12823 shares in the last session.ZF Commercial Vehicle Control System India Ltd witnessed volume of 1199 shares by 10:45 IST on BSE, a 4.62 times surge over two-week average daily volume of 259 shares. The stock increased 3.55% to Rs.13,949.00. Volumes stood at 827 shares in the last session.Tata Consumer Products Ltd notched up volume of 2.05 lakh shares by 10:45 IST on BSE, a 3.99 fold spurt over two-week average daily volume of 51381 shares. The stock rose 1.69% to Rs.1,080.65. Volumes stood at 51954 shares in the last session.Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Ipca Laboratories Ltd soars 1.02%, rises for third straight session
Ipca Laboratories Ltd rose for a third straight session today. The stock is quoting at Rs 1471.7, up 1.02% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.53% on the day, quoting at 25214. The Sensex is at 82662.59, up 0.5%. Ipca Laboratories Ltd has added around 8.01% in last one month. Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has added around 2.68% in last one month and is currently quoting at 22410.35, up 0.98% on the day. The volume in the stock stood at 2.85 lakh shares today, compared to the daily average of 2.23 lakh shares in last one month.The PE of the stock is 45.07 based on TTM earnings ending March 25.Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Ipca Laboratories to hold AGM
Ipca Laboratories announced that the 75th Annual General Meeting(AGM) of the company will be held on 11 August 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Ipca Laboratories fixes record date for final dividend
Ipca Laboratories has fixed 05 August 2025 as record date for payment of final dividend. Powered by Capital Market - Live
2 months agoCapital Market - Live
Spotlight
Ipca Laboratories Ltd spurts 0.19%, up for five straight sessions
Ipca Laboratories Ltd rose for a fifth straight session today. The stock is quoting at Rs 1460.6, up 0.19% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.03% on the day, quoting at 25468.45. The Sensex is at 83519.94, up 0.09%. Ipca Laboratories Ltd has added around 6.67% in last one month. Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has added around 1.19% in last one month and is currently quoting at 22365.05, down 1.25% on the day. The volume in the stock stood at 71760 shares today, compared to the daily average of 2.54 lakh shares in last one month.The PE of the stock is 44.32 based on TTM earnings ending March 25.Powered by Capital Market - Live
2 months agoCapital Market - Live
Spotlight
Ipca Laboratories Ltd soars 1.25%, Gains for third straight session
Ipca Laboratories Ltd is up for a third straight session in a row. The stock is quoting at Rs 1406.8, up 1.25% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.28% on the day, quoting at 25069.95. The Sensex is at 82276.06, down 0.29%. Ipca Laboratories Ltd has added around 0.19% in last one month. Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has added around 4.05% in last one month and is currently quoting at 22057.15, up 0.76% on the day. The volume in the stock stood at 1.55 lakh shares today, compared to the daily average of 2.94 lakh shares in last one month.The PE of the stock is 42.27 based on TTM earnings ending March 25.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Ipca Laboratories consolidated net profit rises 13.81% in the March 2025 quarter
Net profit of Ipca Laboratories rose 13.81% to Rs 67.82 crore in the quarter ended March 2025 as against Rs 59.59 crore during the previous quarter ended March 2024. Sales rose 10.51% to Rs 2246.69 crore in the quarter ended March 2025 as against Rs 2033.03 crore during the previous quarter ended March 2024. For the full year,net profit rose 34.77% to Rs 737.68 crore in the year ended March 2025 as against Rs 547.35 crore during the previous year ended March 2024. Sales rose 16.02% to Rs 8939.59 crore in the year ended March 2025 as against Rs 7705.04 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales2246.692033.03 11 8939.597705.04 16 OPM %19.0915.83 -19.3117.15 - PBDT433.17311.45 39 1734.011307.66 33 PBT333.05213.32 56 1336.19950.42 41 NP67.8259.59 14 737.68547.35 35 Powered by Capital Market - Live
3 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 14.02%, vs industry avg of 9.99%
Over the last 5 years, market share increased from 1.87% to 2.16%
Over the last 5 years, net income has grown at a yearly rate of 4%, vs industry avg of 20.01%